Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...

Avidity Biosciences, Inc. surges on positive developments in AOCs for muscular disorders, strategic partnerships, and ...

2nd October Long MKC: McCormick Extends Uptrend After Strong Q3 Earnings, Targeting Short-Term Gains 2nd October Long ES: ...

After 12 years working for big fashion brands as a Project Manager and Data Analyst,... read more.

Focus is turning to the development of peptide analogues of antibody-derived radiotherapeutics, according to Dr Dave Madge.

Plus: Here’s how Epic founder and CEO Judy Faulkner will keep her medical records company private, independent and ...

Volastra Therapeutics, a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VLS-1488, the company’s internally ...

Poseida Therapeutics' lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.

To say that 2seventy bio’s short two years of existence have been dramatic is an understatement. CEO Chip Baird told BioSpace transparency and a committed staff have kept the biotech going through ...

By leveraging AI, drug developers are moving beyond incremental gains in efficiency and engaging previously undruggable ...

The European Commission has granted conditional approval for Ipsen's IQIRVO (elafibranor) for the <a target=_blank href= ...